The UK Government has announced a new National Cancer Board, which will monitor progress on delivering the ambitions set out in the National Cancer Plan and help drive improvements in cancer diagnosis, treatment and quality of life for people affected by cancer. The Board held its first meeting on 21 September 2026.
Of particular interest to the neuroendocrine cancer community is the appointment of a dedicated clinical lead for rare cancers, recognising that people living with less common cancers often face unique challenges in diagnosis, treatment and access to specialist care. Dr Rob Metcalf has been appointed to this role.
The Board will independently review progress against more than 100 commitments in the National Cancer Plan, identifying areas where improvements are needed and advising ministers on further action. It will meet quarterly and publish annual progress reports.
The Government says the National Cancer Plan aims for three in four people diagnosed with cancer to be cancer-free or living well five years after diagnosis by 2035. Current priorities include earlier diagnosis, faster treatment, greater access to innovative therapies and research, and improved support for people living with and beyond cancer.
Patient organisations representing rare cancers have welcomed the move. Cancer52, which represents charities supporting people with rare and less common cancers, said the Board’s dedicated focus on these cancers is a “landmark commitment” and will help ensure the needs of patients remain central to future cancer planning and service improvements.
For people affected by neuroendocrine cancer, the introduction of a dedicated rare cancers lead offers an important opportunity to ensure that the experiences and needs of those living with NETs and NECs are heard as national cancer services continue to develop.
Source: Department of Health and Social Care and NHS England, “Expert team to drive improvements in cancer care”, 21 September 2026: Full Pres Release here